Q1 2022 Results
Company overview
Financial performance
Financial review
Abbreviations
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
aHUS
ALL
ALS
aBC
AD
Adj.
AIH
Advanced breast cancer
Atopic Dermatitis
Adjuvant
Autoimmune hepatitis
atypical Hemolytic Uremic Syndrome
Acute lymphoblastic leukemia
Amyotrophic lateral sclerosis
HF-REF
HNSCC
HS
ΙΑ
IgAN
iMN
IPF
AMI
Acute myocardial infarction
JIA
AML
Acute myeloid leukemia
jPSA/ERA
aNHL
Agressive non-Hodgkin's lymphoma
AS H2H
Ankylosing spondylitis head-to-head study versus adalimumab
LVEF
mCRPC
BC
Breast cancer
MDR
C3G
C3 glomerulopathy
MDS
CCF
CINDU
Congestive cardiac failure
Chronic inducible urticaria
MS
NASH
CLL
CML
Chronic lymphocytic leukemia
Chronic myeloid leukemia
nHCM
nr-axSpA
Chronic heart failure with reduced ejection fraction
Head and neck squamous cell carcinoma
Hidradenitis suppurativa
Interim analysis
IgA nephropathy
Membranous nephropathy
Idiopathic pulmonary fibrosis
Juvenile idiopathic arthritis
Juvenile psoriatic arthritis / enthesitis-related arthritis
Left ventricular ejection fraction
Metastatic castration-resistant prostate cancer
Multi-drug resistant
Myelodysplastic syndrome
Multiple sclerosis
Non-alcoholic steatohepatitis
Non-obstructive hypertrophic cardiomyopathy
Non-radiographic axial spondyloarthritis
CRC
Colorectal cancer
COPD
Chronic obstructive pulmonary disease
NSCLC
PEF
Non-small cell lung cancer
Preserved ejection fraction
COSP
Chronic ocular surface pain
PedPsO
Pediatric psoriasis
CRSWNP
Severe chronic rhinosinusitis with nasal polyps
PNH
CSU
Chronic spontaneous urticaria
PsA
CVRR-Lp(a)
CVRR-LDLC
DME
Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a)
Secondary prevention of cardiovascular events in patients with elevated levels of LDLC
Diabetic macular edema
PROS
RA
rMS
DLBCL
ESCC
FL
GCA
GVHD
HCC
HD
HFPEF
Diffuse large B-cell lymphoma refractory
Esophageal squamous-cell carcinoma
Follicular lymphoma
Giant cell arteritis
Graft-versus-host disease
Hepatocellular carcinoma
Huntington's disease
Chronic heart failure with preserved ejection fraction
RVO
Retinal vein occlusion
SAA
SLE
SpA
SPMS
TNBC
T1DM
Type 1 Diabetes mellitus
SMA Type 1
SMA Type 2/3
Paroxysmal nocturnal haemoglobinuria
Psoriatic arthritis
PIK3CA related overgrowth spectrum
Rheumatoid arthritis
Relapsing multiple sclerosis
Severe aplastic anemia
Systemic lupus erythematosus
Spinal muscular atrophy (IV formulation)
Spinal muscular atrophy (IT formulation)
Spondyloarthritis
Secondary progressive multiple sclerosis
Triple negative breast cancer
120 Investor Relations | Q1 2022 Results
References
Abbreviations
U NOVARTIS | Reimagining MedicineView entire presentation